Equities

Bafna Pharmaceuticals Ltd

BAFNAPH:NSI

Bafna Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)77.08
  • Today's Change-1.92 / -2.43%
  • Shares traded4.88k
  • 1 Year change-12.36%
  • Beta1.3394
Data delayed at least 15 minutes, as of Sep 20 2024 10:57 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments21781.73
Total Receivables, Net615559155
Total Inventory304232203
Prepaid expenses4.613.73--
Other current assets, total----149
Total current assets945873509
Property, plant & equipment, net507402388
Goodwill, net------
Intangibles, net18150
Long term investments----4.19
Note receivable - long term------
Other long term assets7.355.42--
Total assets1,4771,296901
LIABILITIES
Accounts payable354285124
Accrued expenses0.901.10--
Notes payable/short-term debt10014557
Current portion long-term debt/capital leases36----
Other current liabilities, total493439
Total current liabilities541465220
Total long term debt1088453
Total debt244229111
Deferred income tax------
Minority interest------
Other liabilities, total20128.51
Total liabilities668561282
SHAREHOLDERS EQUITY
Common stock237237237
Additional paid-in capital754754--
Retained earnings (accumulated deficit)(182)(256)383
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity808735620
Total liabilities & shareholders' equity1,4771,296901
Total common shares outstanding242424
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.